ABSTRACT
For the low-risk or stable patients with acute myocardial infarction post percutaneous coronary intervention, compared with moderate-intensity continuous training, high-intensity interval training (HIIT) can better enhance aerobic capacity and protect the cardiovascular system by significantly lowering the inflammatory response, improving endothelial function as well as reversing the progress of ventricular remodeling. HIIT is safety and the patients are more compliant. However, further research is needed on the application of high-risk patients. The standard protocol of HIIT according to the risk stratification also requires further discussion.
ABSTRACT
Objectives: This study was designed to assess whether measurement of the index of microvascular resistance (IMR) before and following percutaneous coronary intervention (PCI) could help identify patients who develop periprocedural myocardial infarction (PPMI). Methods: 54 patients with stable coronary artery disease undergoing elective PCI were divided into PPMI group and no-PPMI group. IMR and FFR was measured before and following percutaneous coronary intervention (PCI) with a pressure wire. Times of balloon inflation was also analyzed. hs-TnI at 24 h post PCI was measured. rPIMR value was calculated. Results: IMR obtained at pre-PCI and post-PCI as well as rPIMR were significantly higher in PPMI patients than in no-PPMI patients (22.02±2.92 vs 17.46±3.44, 25.86±3.04 vs 18.96±2.84, 1.22±0.21 vs 0.94±0.24, all P<0.05, respectively). Patients with PPMI more frequently underwent pre- and post-dilatation(70.8% vs 36.7%, 54.2% vs 23.3%, P<0.05), respectively, the number of balloon inflations was significantly higher in patients with PPMI than in no-PPMI patients (4.33±1.79 vs 3.20±1.63, P<0.05). The area under the ROC curve for predicting PPMI event by pre-PCI IMR was 0.941 (95%CI: 0.884-0.998, P<0.05), cut-off value was 19.91 (sensitivity: 95.8% and specificity: 77.0%). Multivariate logistic analysis showed that pre- and post-PCI IMR, rPIMR were positively correlated with PPMI (all P<0.05). Conclusions: Measuring IMR and rPIMR may allow prospective identification of patients at increased risk of PPMI.
ABSTRACT
Objective To study the effect of Thy-1.1 stem cell transplantation on endothelial hyperplasia and restenosis.Methods Thirty 4-6 weeks male SD rats were sacrificed to obtain the Thy-1.1 stem cells.Carotid artery were injured by ballon in sixty female SD rat's were randomized to receive stem cell transplantation(5?10~6 Thy-1.1,n=30)or saline approach(n=30).About 5?10~6 Thy-1.1 stem cells were injected into the injured arter- y after carotid artery injury;while the control rats underwent carotid artery injury and was injected the same amount of saline.The animals were sacrificed,3,7,14,21 and 28 days after balloon denudation.The samples of carotid artery were harvested for pathological examination,RT-PCR and in situ hyhridzation(ISH)were used to detect the transplanted cells in the injured artery.Results The intimal thickness was thinner in stem cell transplantation group(I/M,Stem cell transplantation group:2.06?0.28 vs control group 2.42?0.19,P
ABSTRACT
<p><b>OBJECTIVE</b>To qualitatively and quantitatively assess the evidence regarding the relation of ACE I/D polymorphism to coronary heart disease (CHD) risk.</p><p><b>METHODS</b>Medline (January 1994 to February 2005) and China Hospital Knowledge Databases (January 1994 to May 2005) were retrieved for all publications relating to case-control studies reporting a link between CHD risk factors and the ACE I/D polymorphism. All 16 association studies were identified and a meta-analysis was conducted by using the RevMan 4.2 estimate for odds ratio (OR) to determine whether the DD genotype might predict the outcome in CHD.</p><p><b>RESULTS</b>Sixteen out of 48 identified studies reporting data on 1345 CHD patients and 1286 matched controls fulfilled these inclusion criteria. The overall distribution of genotypes in the control subjects was 35.88% II, 40.86% ID, and 23.26% DD. The odds ratio for CHD for DD versus ID/II genotypes across all studies was 2.56 [95% CI, 2.09 - 3.13]. The relative CHD risk appeared to be increased with the D allele (chi(Trend)(2) = 97.12, P < 0.01).</p><p><b>CONCLUSIONS</b>ACE gene I/D polymorphism should be associated with susceptivity of coronary heart disease in China. The CHD risk is increased significantly in individuals with DD genotypes. The ACE D allele should be a risk factor for CHD.</p>
Subject(s)
Humans , Alleles , China , Coronary Disease , Genetics , Gene Deletion , Genetic Predisposition to Disease , Peptidyl-Dipeptidase A , Genetics , Polymorphism, Restriction Fragment LengthABSTRACT
<p><b>OBJECTIVE</b>To assess the safety and effects of 40 mg atorvastatin on serum lipids, inflammatory markers and clinical events in ACS patients post PCI.</p><p><b>METHODS</b>A total of 92 patients with ACS post successful PCI were randomly divided into atorvastatin 10 mg/d (group A) and atorvastatin 40 mg/d (group B) on top of the standard medical therapy. Blood were taken at baseline, 4, 12 and 24 weeks for serum alanine aminotransferase (ALT), lipids, high-sensitive C-reactive protein (hs-CRP) and matrix metalloprotease-9 (MMP-9) measurements. The major adverse cardiac events (MACE) were also observed.</p><p><b>RESULTS</b>There was no significant difference in medication withdrawn (2 vs. 3 cases) due to increased ALT (3 times higher than normal) and incidence of MACE (5 vs. 7 cases) between the groups. TC and LDL were significantly reduced in both groups 4 weeks and thereafter post medication compared to pre-treatment (P < 0.05) and the reduction was more significant in group B than that in group A at 24 weeks post medication (P < 0.05) while TG and HDL remained unchanged. hs-CRP was significantly reduced at 12 and 24 weeks in both groups compared to baseline and the reduction was more significant in group B than that in group A at 24 weeks. MMP-9 was significantly reduced in both groups 4 weeks and thereafter post medication compared to pre-treatment (P < 0.05) and the reduction was more significant in group B than that in group A at 12 weeks post medication (P < 0.05).</p><p><b>CONCLUSION</b>Both atorvastatin doses significantly reduced TC, LDL, hs-CRP and MMP-9 in ACS patients post PCI and the reduction was more significant in high dose atorvastatin group at 24 weeks while the MACE and drug withdraw rates were similar between the groups.</p>